This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
HealthdirectFree Australian health advice you can count on.
50 mg/1, Tablet, film coated
INN: VENETOCLAX
Data updated: 2026-04-25
Available in:
🇬🇧🇵🇹
Form
TABLET, FILM COATED
Dosage
50 mg/1
Route
ORAL
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
AbbVie Inc.
ATC Code
L01XX52
Source
OPENFDA_NDC
(
ARTG
)
Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma
VENCLEXTA in combination with obinutuzumab is indicated for the treatment of patients with
chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
VENCLEXTA in combination with ibrutinib is indicated for the treatment of adult patients with
previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).
VENCLEXTA in combination with rituximab is indicated for the treatment of adult patients with
chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
VENCLEXTA monotherapy is indicated for the treatment of:
patients with relapsed or refractory CLL with 17p deletion, or
patients with relapsed or refractory CLL for whom there are no other suitable treatment
options.
Acute Myeloid Leukaemia
VENCLEXTA, in combination with azacitidine or low-dose cytarabine, is indicated for the
treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are
ineligible for intensive chemotherapy.
⚠️ Warnings
• Avoid using the drug if you are planning to become pregnant or are already pregnant as the drug may harm the fetus. Lactating women should not use venetoclax as the drug may get excreted through breast milk.
• Do not drink grapefruit juice and do not use drugs which are CYP3A inhibitors with venetoclax as they may increase the risk of a serious condition known as Tumor Lysis Syndrome (TLS). This condition occurs when the drug causes fast and abnormal breakdown of cancer cells leading to kidney failure and other life threatening events. Drink excess of water while taking the drug to avoid TLS.
• Venetoclax requires regular monitoring of the blood cell counts as the drug might result in severe neutropenia (decreased neutrophil (white blood cells) count in the blood).
• Do not vaccinate the patient with live attenuated vaccines before, after or during the treatment with venetoclax as the drug is capable of reducing the effectiveness or safety of the vaccines.
